10-Q: Senseonics Holdings Reports Q3 2024 Results, Faces Going Concern Uncertainty Amidst Product Transition

Senseonics Holdings reported a net loss for Q3 2024 and acknowledged substantial doubt about its ability to continue as a going concern due to ongoing losses and the need for additional funding.

Summary

• Senseonics Holdings reported a net loss of $23.976 million for the third quarter of 2024, compared to a net loss of $24.103 million for the same period in 2023.
• Total revenue decreased to $4.263 million in Q3 2024 from $6.097 million in Q3 2023, primarily due to a planned wind-down of E3 inventory.
• The company's cost of sales increased to $8.314 million in Q3 2024, up from $4.925 million in Q3 2023, resulting in a gross loss of $4.051 million.
• Research and development expenses decreased to $10.546 million in Q3 2024 from $12.769 million in Q3 2023, mainly due to reduced clinical study spending.
• Selling, general, and administrative expenses increased to $8.250 million in Q3 2024 from $7.425 million in Q3 2023.
• For the nine months ended September 30, 2024, the company's net loss was $63.140 million, compared to a net loss of $43.202 million for the same period in 2023.
• The company's total revenue for the nine months ended September 30, 2024 was $14.175 million, slightly down from $14.360 million in the same period of 2023.
• The company had a gross loss of $3.418 million for the nine months ended September 30, 2024.
• As of September 30, 2024, Senseonics had unrestricted cash, cash equivalents, and marketable securities of $74.5 million.
• The company has determined that substantial doubt exists regarding its ability to continue as a going concern for the one-year period following the date these financial statements are issued.
• Senseonics will require additional funding to sustain operations beyond the next year and is exploring various financing options.
• The company received FDA approval for its 365-day Eversense product in September 2024 and began commercialization in the fourth quarter of 2024.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including a net loss, decreased revenue, and a going concern warning. While there are positive developments like FDA approval and new product development, the overall sentiment is negative due to the company's financial instability and reliance on external funding.

Positives

• FDA approval was obtained for the 365-day Eversense CGM system.
• First-in-human testing for the Gemini system was initiated.
• The company has expanded Medicare coverage for Eversense E3 to include more patients.
• A new subsidiary, Eon Care, was established to support patient access to the Eversense system.
• The company has secured additional funding through a registered direct offering and concurrent private placement of warrants.

Negatives

• The company reported a net loss for both the three and nine months ended September 30, 2024.
• Total revenue decreased in Q3 2024 compared to Q3 2023.
• The company's cost of sales increased, leading to a gross loss in Q3 2024.
• The company has determined that substantial doubt exists regarding its ability to continue as a going concern.
• The company is reliant on a single customer, Ascensia, for a significant portion of its revenue.

Risks

• The company's ability to continue as a going concern is uncertain due to ongoing losses and the need for additional funding.
• The company is subject to patent litigation, which could be costly and disruptive.
• The company's success depends on the commercialization and adoption of its products, which is subject to market and regulatory risks.
• The company is reliant on a single customer, Ascensia, for a significant portion of its revenue.
• The company's debt obligations and covenants could restrict its operations and financial flexibility.

Future Outlook

The company anticipates that its principal uses of cash in the future will be primarily to fund its operations, working capital needs, capital expenditures and other strategic initiatives. The company will require additional funding to sustain operations beyond the next year and is exploring various financing options, including public or private debt and equity financings, collaborations, strategic alliances, and licensing arrangements.

Management Comments

• Management has determined that substantial doubt exists regarding its ability to continue as a going concern for the one-year period following the date these condensed consolidated financial statements are issued.
• Management is evaluating strategies to obtain the required additional funding for future operations.

Industry Context

The medical device industry, particularly the glucose monitoring sector, is highly competitive and characterized by rapid technological advancements. Senseonics is competing with established players in the CGM market and is focused on differentiating its implantable technology. The company's transition to the 365-day product and development of next-generation products like Gemini are aimed at gaining a competitive edge.

Comparison to Industry Standards

• Senseonics' revenue is significantly lower than major competitors in the CGM market, such as Dexcom and Abbott, which have established market positions and broader product portfolios.
• The company's gross margin is currently negative due to one-time charges related to the product transition, while industry leaders typically maintain high gross margins.
• Senseonics' reliance on a single customer, Ascensia, for a large portion of its revenue is a significant risk compared to competitors with diversified customer bases.
• The company's substantial doubt about its ability to continue as a going concern is a major concern, while established competitors have strong financial positions.
• The company's research and development spending is lower than some of its larger competitors, which may impact its ability to innovate and compete in the long term.
• The company's focus on long-term implantable CGM technology is a differentiator, but it also presents unique challenges in terms of regulatory approvals and market adoption compared to traditional CGM systems.

Legal Proceedings

• The company is involved in a patent infringement lawsuit filed by Cellspin Soft, Inc.
• The company is defending against a lawsuit alleging violations of the False Claims Act, which was dismissed by the district court and affirmed by the Fifth Circuit Court of Appeals.

Related Party Transactions

• The company has significant revenue from sales to Ascensia, a related party.
• The company purchases certain medical supplies from Ascensia for clinical trials.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be impacted by potential cost-cutting measures or restructuring.
• Customers may be affected by potential delays or changes in product availability.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company will continue to monitor its capital structure and market conditions.
• The company will explore public or private debt and equity financings and other sources of capital.
• The company will continue to develop and commercialize its Eversense CGM systems.
• The company will seek CE mark authorization for Eversense 365 in the first quarter of 2025.
• The company will utilize data from first-in-human testing for the Gemini system for an IDE submission anticipated in the second half of 2025.

Key Dates

Keywords

Eversense, CGM, continuous glucose monitoring, diabetes, medical device, FDA approval, financial results, going concern, revenue, net loss, product development, Ascensia, funding, debt, warrants